TY - JOUR
T1 - Immunotherapy of cancer
AU - Borghaei, Hossein
AU - Smith, Mitchell R.
AU - Campbell, Kerry S.
PY - 2009/12/25
Y1 - 2009/12/25
N2 - Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments.
AB - Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments.
KW - Animals
KW - Antibodies, Monoclonal/immunology
KW - Dendritic Cells/immunology
KW - Humans
KW - Immunotherapy/methods
KW - Killer Cells, Natural/immunology
KW - Neoplasms/immunology
KW - Radioimmunotherapy/methods
KW - T-Lymphocytes/immunology
KW - Toll-Like Receptors/agonists
UR - http://www.scopus.com/inward/record.url?scp=71749114348&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000272748300005&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.ejphar.2009.09.067
DO - 10.1016/j.ejphar.2009.09.067
M3 - Review article
C2 - 19837059
SN - 0014-2999
VL - 625
SP - 41
EP - 54
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -